September 13, 2023
BullFrog AI Announces Strategic Partnership with Lieber Institute for Brain Development
GAITHERSBURG, Md., Sept. 13, 2023 — BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced […]
Learn MoreAugust 09, 2023
LIBD Research Uncovers Breakthrough in Predicting Risk for Schizophrenia
A novel approach to existing functional neuroimaging datasets led to a breakthrough in understanding genetic and clinical risk for schizophrenia in the context of how brain regions communicate with each other. The research was published in PNAS—read the paper here. […]
Learn MoreJuly 10, 2023
LIBD CEO Named PennMedicine Distinguished Graduate
Lieber Institute CEO and Director Dr. Daniel Weinberger was honored by his alma mater, the Perelman School of Medicine at the University of Pennsylvania, with the 2023 Distinguished Graduate Award. Dr. L. Scott Levin, chair of the PennMedicine Department of […]
Learn MoreMay 15, 2023
NEW STUDY FINDS THE PLACENTA, NOT ONLY THE BRAIN, PLAYS A CENTRAL ROLE IN GENETIC RISK OF SCHIZOPHRENIA
More than 100 genes linked to the risk of schizophrenia seem to cause illness because of their role in the placenta rather than in the developing brain, according to a new study from the Lieber Institute for Brain Development.
Learn More
Genes and Behavior
